Medidata Solutions (MDSO) Holdings Decreased by Rhumbline Advisers

Rhumbline Advisers reduced its position in Medidata Solutions (NASDAQ:MDSO) by 5.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 116,140 shares of the company’s stock after selling 6,856 shares during the quarter. Rhumbline Advisers owned approximately 0.20% of Medidata Solutions worth $7,295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Meadow Creek Investment Management LLC boosted its position in shares of Medidata Solutions by 31.4% in the fourth quarter. Meadow Creek Investment Management LLC now owns 3,680 shares of the company’s stock worth $233,000 after purchasing an additional 880 shares during the period. Essex Investment Management Co. LLC boosted its position in shares of Medidata Solutions by 8.7% in the fourth quarter. Essex Investment Management Co. LLC now owns 11,085 shares of the company’s stock worth $702,000 after purchasing an additional 886 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Medidata Solutions by 48.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock worth $205,000 after purchasing an additional 1,056 shares during the period. TIAA CREF Investment Management LLC boosted its position in shares of Medidata Solutions by 0.8% in the fourth quarter. TIAA CREF Investment Management LLC now owns 159,860 shares of the company’s stock worth $10,130,000 after purchasing an additional 1,194 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Medidata Solutions by 4.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 37,821 shares of the company’s stock worth $2,397,000 after purchasing an additional 1,639 shares during the period.

In other Medidata Solutions news, CFO Rouven Bergmann sold 2,000 shares of the stock in a transaction on Monday, March 19th. The shares were sold at an average price of $66.30, for a total transaction of $132,600.00. Following the completion of the transaction, the chief financial officer now owns 94,744 shares in the company, valued at $6,281,527.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael I. Otner sold 10,395 shares of the stock in a transaction on Wednesday, April 25th. The shares were sold at an average price of $70.05, for a total transaction of $728,169.75. Following the transaction, the executive vice president now owns 74,165 shares of the company’s stock, valued at approximately $5,195,258.25. The disclosure for this sale can be found here. Insiders have sold 45,231 shares of company stock valued at $3,166,939 in the last quarter. 4.70% of the stock is owned by company insiders.

Shares of Medidata Solutions opened at $77.54 on Friday, MarketBeat Ratings reports. Medidata Solutions has a fifty-two week low of $59.60 and a fifty-two week high of $85.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.63 and a quick ratio of 1.63. The firm has a market cap of $4.53 billion, a P/E ratio of 91.22, a P/E/G ratio of 3.83 and a beta of 1.49.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings data on Thursday, April 19th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.05. Medidata Solutions had a net margin of 7.96% and a return on equity of 11.36%. The business had revenue of $149.20 million during the quarter, compared to analyst estimates of $146.73 million. During the same quarter last year, the business earned $0.31 earnings per share. Medidata Solutions’s quarterly revenue was up 16.9% compared to the same quarter last year. research analysts anticipate that Medidata Solutions will post 0.98 earnings per share for the current year.

A number of equities analysts have weighed in on MDSO shares. TheStreet upgraded shares of Medidata Solutions from a “c+” rating to a “b-” rating in a research report on Monday, March 12th. Zacks Investment Research upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 14th. Needham & Company LLC dropped their target price on shares of Medidata Solutions to $75.00 and set a “buy” rating for the company in a research report on Friday, February 9th. BidaskClub upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research report on Friday, May 4th. Finally, Dougherty & Co restated a “buy” rating and set a $89.00 target price (up previously from $79.00) on shares of Medidata Solutions in a research report on Thursday, May 10th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Medidata Solutions has an average rating of “Buy” and a consensus price target of $83.71.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions (NASDAQ:MDSO).

Institutional Ownership by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply